Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.64 |
| ▸ | IGF1R | P08069 | 4/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
| ▸ | BTK | Q06187 | 3/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.64 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.64 |
| ▸ | CDC7 | O00311 | 1/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | STK25 | O00506 | 1/20 | 0.64 |
| ▸ | CIT | O14578 | 1/20 | 0.64 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | IKBKB | O14920 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12212971 | 0.97 | SYK (0.60) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2526079 | 0.93 | SYK (0.64) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2524410 | 0.93 | SYK (0.63) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2518402 | 0.92 | SYK (0.57) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2526128 | 0.92 | SYK (0.60) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2523825 | 0.92 | SYK (0.62) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2524923 | 0.92 | SYK (0.62) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2523824 | 0.91 | SYK (0.60) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2521971 | 0.91 | SYK (0.60) | SYKCDK2IGF1RFLT3BTK | |
| SCHEMBL2519001 | 0.91 | SYK (0.61) | SYKCDK2IGF1RFLT3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2501705-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011063241-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | SYK 1871/4885CDK2 49/4885IGF1R 4597/4885 |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | SYK 2355/4885CDK2 55/4885IGF1R 4617/4885 |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | SYK 2355/4885CDK2 55/4885IGF1R 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.